ConductScience.org, home

Paper3708002

Iron mobilisation from lactoferrin by chelators at physiological pH.

Kontoghiorghes GJ. Biochim Biophys Acta, 1986. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. Iron mobilisation from lactoferrin by chelators at physiological pH. Papers, record 3708002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3708002

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Iron mobilisation from lactoferrin by chelators at physiological pH.
PubMed
Journal
Biochim Biophys Acta
PubMed
Year
1986
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
1.17
iCite
Revised in PubMed
2019-06-09
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kontoghiorghes GJG J

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IronMajor topic
LactoferrinMajor topic
LactoglobulinsMajor topic
Chelating Agents
Female
Humans
Hydrogen-Ion Concentration
Milk, Human

Source PubMed

Download CSV of topics

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
41596074Targeting Aging and Diseases Associated with Ferroptosis and Senescence Through Modulation of Iron, Oxidative Stress and Lipid Peroxidation.Antioxidants (Basel)2025https://conductscience.org/library/papers/41596074PubMed
41156522Development of Iron-Chelating/Antioxidant Nutraceuticals and Natural Products as Pharmaceuticals for Clinical Use in Diseases with Free Radical Pathologies.Nutrients2025https://conductscience.org/library/papers/41156522PubMed
39857363New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites.Antioxidants (Basel)2024https://conductscience.org/library/papers/39857363PubMed
38892142
Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues.
Int J Mol Sci2024https://conductscience.org/library/papers/38892142PubMed
37513928The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513928PubMed
36430469New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer.Int J Mol Sci2022https://conductscience.org/library/papers/36430469PubMed
35163169Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine.Int J Mol Sci2022https://conductscience.org/library/papers/35163169PubMed
34074010New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.Int J Mol Sci2021https://conductscience.org/library/papers/34074010PubMed
32751493Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.Medicines (Basel)2020https://conductscience.org/library/papers/32751493PubMed
32545424Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.Cells2020https://conductscience.org/library/papers/32545424PubMed
27822363Structure and domain dynamics of human lactoferrin in solution and the influence of Fe(III)-ion ligand binding.BMC Biophys2016https://conductscience.org/library/papers/27822363PubMed
27019793New developments and controversies in iron metabolism and iron chelation therapy.World J Methodol2016https://conductscience.org/library/papers/27019793PubMed
26610453Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.Molecules2015https://conductscience.org/library/papers/26610453PubMed
12825969Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.Drug Saf2003https://conductscience.org/library/papers/12825969PubMed
8262586Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.Indian J Pediatr1993https://conductscience.org/library/papers/8262586PubMed
3122880Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Br Med J (Clin Res Ed)1987https://conductscience.org/library/papers/3122880PubMed
2805610Iron-binding proteins and free iron in synovial fluids of rheumatoid arthritis patients.Clin Rheumatol1989https://conductscience.org/library/papers/2805610PubMed
1723362Drug antioxidant effects. A basis for drug selection?Drugs1991https://conductscience.org/library/papers/1723362PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3708002

GET https://conductscience.org/api/papers/v1/3708002/authors